Researchers have developed RegDivergence-101, a new benchmark designed to evaluate Large Language Models (LLMs) in detecting contradictions and silences between regulatory documents from different jurisdictions, specifically focusing on the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in the life sciences sector. The benchmark aims to automate the manual process currently undertaken by regulatory affairs experts when reconciling differing or absent guidance between these agencies. Initial experiments show that while flat LLMs like Claude (Haiku) perform well, methods incorporating obligation-level graph representations show promise for large-scale detection of regulatory silences. AI
IMPACT This benchmark could streamline regulatory compliance for life sciences companies operating in multiple jurisdictions.
RANK_REASON The cluster describes a new academic benchmark and evaluation methodology for LLMs. [lever_c_demoted from research: ic=1 ai=1.0]
- Claude (Haiku)
- European Medicines Agency
- European Union
- Graph RAG
- RegDivergence-101
- United States
- United States Food and Drug Administration
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →